Materiały źródłowe

• #1 Adrenoleukodystrophy – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK562328/

  Adrenoleukodystrophy is a rare genetic peroxisomal disorder characterized by the abnormal metabolism of very long-chain fatty acids (VLCFAs) due to mutations in the ABCD1 gene. […] Diagnosis typically involves clinical suspicion prompted by neurological symptoms and biochemical testing showing elevated VLCFAs. Genetic confirmation through DNA analysis of ABCD1 gene mutations is crucial for a definitive diagnosis. […] The evaluation of adrenoleukodystrophy begins with considering the typical clinical presentation, characteristics, symptoms, signs, and suggestive family history. Several states have introduced newborn screening tests to identify infants with X-ALD. Including X-ALD in newborn screening programs helps identify affected newborns early, allowing for intervention before symptoms develop.

• #1 Adrenoleukodystrophy (ALD) | Boston Children’s Hospital

  https://www.childrenshospital.org/conditions/adrenoleukodystrophy-ald

  Genetic testing can identify the ABCD1 gene mutation that causes ALD. It also can accurately identify other members of the family who have ALD but may not be showing symptoms. […] Early diagnosis of the cerebral form of ALD is critical, because there is a narrow window during which the neurological damage can be prevented. Once the disease progresses, there is no way to replace the lost myelin or reverse the neurological damage already done. […] A newborn screening test was added to the United States Recommended Uniform Newborn Screening Panel in 2016 and is currently is available in many states. It detects elevated VLCFA levels in the blood, a clear indicator of ALD. With newborn screening, boys at risk for CALD can be identified and treated early. […] When clinicians suspect CALD, they will perform tests including a magnetic resonance imaging (MRI) scan to determine whether there is damage to the brain tissue and a blood test to measure the concentration of VLCFAs. Genetic testing may be performed at this time or later. Boys who have ALD have regularly scheduled MRIs to watch for the development of CALD.

• #1 Diagnosis of ALD |

  https://adrenoleukodystrophy.info/clinical-diagnosis/diagnosis-of-ald

  The diagnosis of adrenoleukodystrophy should be considered in four distinct clinical situations: […] Diagnosis is based on clinical features, most commonly progressive spastic paraparesis, and a panel of laboratory tests. […] Brain MRI is always abnormal in neurologically symptomatic men and often provides the first diagnostic clue. […] The most commonly used laboratory test worldwide for the diagnosis of ALD is the measurement of plasma very long-chain fatty acid (VLCFA) concentrations. […] Increased levels of VLCFA in plasma and/or cultured skin fibroblasts is present in approximately 85% of women with ALD; 15-20% of known women with ALD have normal plasma levels of VLCFA. […] VLCFA containing C26:0-lysoPC is elevated in all men and 99% women with ALD and is used in newborn screening for ALD.

• #1 X-Linked Adrenoleukodystrophy | Choose the Right Test

  https://arupconsult.com/content/x-linked-adrenoleukodystrophy

  Laboratory testing for X-ALD is used to diagnose X-ALD in infants with positive newborn screening results, boys with signs of childhood cerebral adrenoleukodystrophy (CCALD), and males with signs of adrenomyleoneuropathy. […] VLCFA concentrations are typically increased in male patients with X-ALD, regardless of disease status or patient age. […] Measurement of VLCFAs in plasma can be used to diagnose X-ALD in males, and has a high sensitivity for the disease. […] Genetic testing therefore is typically used to definitively diagnose the disease and to identify female carriers. […] Monitoring is necessary in patients with X-ALD to detect disease progression and identify patients for whom treatment is indicated.

• #1 Adrenoleukodystrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/adrenoleukodystrophy/diagnosis-treatment/drc-20369160

  To diagnose ALD, your doctor will review your symptoms and your medical and family history. Your doctor will conduct a physical examination and order several tests, including: […] Blood testing. These tests check for high levels of very long-chain fatty acids (VLCFAs) in your blood, which are a key indicator of adrenoleukodystrophy. Doctors use blood samples for genetic testing to identify defects or mutations that cause ALD. Doctors also use blood tests to evaluate how well your adrenal glands work. […] MRI. Powerful magnets and radio waves create detailed images of your brain in an MRI scan. This allows doctors to detect abnormalities in your brain that could indicate adrenoleukodystrophy, including damage to the nerve tissue (white matter) of your brain. Doctors may use several types of MRI to view the most-detailed images of your brain and detect early signs of leukodystrophy. […] Skin biopsy and fibroblast cell culture. A small sample of skin may be taken to check for increased levels of VLCFA in some cases.

• #1 X-Linked Adrenoleukodystrophy – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1315/

  X-ALD is characterized by progressive behavioral, cognitive, and neurologic deficits; onset of symptoms ranges from childhood (typically ages 4 to 8 years) to adolescence (ages 11 to 21 years) and adulthood. […] The diagnosis is established by identification of a hemizygous ABCD1 pathogenic variant in a male or a heterozygous ABCD1 pathogenic variant in a female on molecular genetic testing. […] The three scenarios in which X-linked adrenoleukodystrophy (X-ALD) may be considered are a positive newborn screening result, a symptomatic individual, and a male who is asymptomatic but identified by family screening. […] Newborn screening (NBS) for X-ALD has been added to the recommended uniform screening panel in the United States and, to date, more than half the states have begun screening.

• #1 X-Linked Adrenoleukodystrophy – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1315/

  The diagnosis of X-ALD is established in a male proband with suggestive findings, elevated VLCFAs, and a hemizygous pathogenic variant in ABCD1 identified by molecular genetic testing. […] The diagnosis of X-ALD is established in a female proband with suggestive findings, elevated VLCFAs or C26:0-LPC, and a heterozygous pathogenic variant in ABCD1 identified by molecular genetic testing.

• #1 Diagnosis of ALD |

  https://adrenoleukodystrophy.info/clinical-diagnosis/diagnosis-of-ald

  The ABCD1 gene is the only gene associated with adrenoleukodystrophy. […] Boehm and colleagues have developed and validated a robust DNA diagnostic test for adrenoleukodystrophy involving non-nested genomic amplification of the adrenoleukodystrophy gene, followed by fluorescent dye primer sequencing and analysis. […] Adrenoleukodystrophy is inherited in an X-linked pattern. […] Testing at-risk female relatives for carrier status is a two-step process. […] Prenatal diagnosis to detect a possible affected male fetus can be offered to women whose carrier status has been clearly confirmed by genetic analysis of the ABCD1 gene. […] Early diagnosis of adrenoleukodystrophy is key to saving lives because newborn screening allows prospective monitoring of adrenal function and the onset of cerebral ALD.

• #1 Adrenoleukodystrophy – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK562328/

  Laboratory workup may show abnormal liver function and a reduced response to adrenocorticotropic hormone administration. More specific indicators of adrenoleukodystrophy include elevated concentrations of VLCFAs in plasma, skin fibroblasts, and amniocytes. […] Magnetic resonance imaging (MRI) of the brain is crucial for the evaluation of adrenoleukodystrophy. Typical MRI findings include a white matter demyelination pattern, microgyria, and germinolytic cysts in the caudothalamic groove. Further genetic testing to identify the specific mutation causing the disorder is recommended to confirm the diagnosis. […] Diagnosis of adrenoleukodystrophy requires a detailed history, physical examination, and diagnostic modalities that include VLCFA measurement, brain MRI, and specific genetic testing.

• #1 ALD Phenotypes: Cerebral ALD | ALD Connect

  https://aldconnect.org/what-is-ald/cerebral-ald/

  Cerebral ALD is primarily diagnosed through brain MRI. Individuals with cerebral ALD will show white matter changes, often accompanied by contrast enhancement visualized with gadolinium. A “Loes Score” is assigned to describe the severity of these white matter changes, which helps guide treatment decisions and predict prognosis. […] Early diagnosis is crucial. Brain MRI changes can appear before any symptoms develop, allowing for potentially life-saving intervention. Regular monitoring through MRI scans and neurological assessments is essential for detecting the onset of cerebral involvement in both boys and men with ALD. […] International consensus guidelines recommend that all boys and men with ALD be monitored by MRI for the development of cerebral ALD even in the absence of neurological symptoms. Monitoring is crucial to preserve the best chances for a good outcome, as treatment options are most successful when pursued at the early stages of cerebral ALD progression.

• #1 How is ALD Monitored & Managed? | It Might Be ALD

  https://www.itmightbeald.com/ald-monitoring-management

  Vigilant MRI monitoring can help identify progression to cerebral adrenoleukodystrophy (ALD). Cerebral ALD is a rapidly progressing, life-threatening disease that should be diagnosed as early as possible to help prevent irreversible brain damage. Regular MRI scans in boys diagnosed with ALD are critical to detect white matter changes indicative of progression to cerebral ALD. […] White matter changes on MRI precede the onset of symptoms, so MRI monitoring is critical as it can detect progression to cerebral ALD before any symptoms arise. […] Since there is no way to predict which patients with ALD will progress to cerebral ALD, it is important to detect cerebral ALD via MRI as early as possible, as the disease can progress very rapidly. […] Brain changes detected through MRI precede the onset of clinical symptoms of cerebral ALD by months; once these symptoms develop, it is often too late to treat effectively because of the rapid progression of the disease.

• #1 Adrenoleukodystrophy Clinical Practice Guidelines – 2022 Guideline Summary for Adrenoleukodystrophy

  https://www.guidelinecentral.com/guideline/2306198/

  All boys and men with ALD should be screened for cerebral ALD, including in the absence of neurologic or cognitive symptoms. […] A baseline MRI scan should be obtained at age 2 years. Between 2 and 12 years, male patients should be screened every 6 months. From age 12 years, screening should be yearly. […] Nonimaging biomarkers for the diagnosis of cerebral ALD are not indicated outside of a research setting. […] Transplantation eligibility should be determined by an ALD transplantation expert. […] If adrenal insufficiency is present, we recommend glucocorticoid replacement therapy by an endocrinologist.

• #1 Adrenoleukodystrophy | MedLink Neurology

  https://www.medlink.com/articles/adrenoleukodystrophy

  Genetic testing is especially important in patients with borderline very long-chain fatty acid levels or atypical features and female patients with symptoms or family history of adrenoleukodystrophy due to the less sensitive results of very long-chain fatty acid testing. […] Adrenal function should always be evaluated in the patients with X-linked adrenoleukodystrophy diagnosis. […] Once a diagnosis is made based on genetic biochemical screening, there are currently no reliable biomarkers to help with the prediction of the likely phenotype in the patient. […] Brain MRI studies are of great diagnostic value for the childhood, adolescent, and adult cerebral forms of adrenoleukodystrophy. […] The cerebral white matter involvement typically begins from the splenium of the corpus callosum and progresses to the periventricular and occipital regions. […] The posterior predominant T2 hyperintensity forms the most common MRI finding in the whole cohort and in children and adolescent age groups.

• #1 ALD: Adrenoleukodystrophy, Disease, X-Linked

  https://my.clevelandclinic.org/health/diseases/6030-adrenoleukodystrophy-ald

  Adrenoleukodystrophy (ALD) is a genetic disorder connected to the X chromosome. […] Treatment focuses on stopping or slowing the diseases progression and improving symptoms. […] ALD is a progressive disease. Treatments aim to slow the progression and improve peoples quality of life. […] Some infants are diagnosed at birth during newborn screening. Newborn screening tests babies for certain diseases. About a dozen states screen for ALD during newborn screening in the hospital. More often, parents or providers notice symptoms in a childs early years. […] Healthcare providers evaluate your childs medical and family history. If the provider suspects ALD, your child may have: Blood test to measure levels of VLCFA. Genetic test to look for gene changes linked to ALD or other conditions. Adrenocorticotropic hormone (ACTH) stimulation test to check adrenal gland function. MRI to see how ALD has affected the brain.

• #1 Adrenoleukodystrophy Clinical Practice Guidelines – 2022 Guideline Summary for Adrenoleukodystrophy

  https://www.guidelinecentral.com/guideline/2306198/

  Cerebral ALD should be considered in boys and men with white matter abnormalities on brain MRI in a pattern suggestive of ALD with or without cognitive and neurologic symptoms. […] ALD-related myelopathy should be considered in adult men and women with signs or symptoms of chronic myelopathy (gait disorder, spastic paraparesis, sphincter disturbances) with a normal MRI. […] ALD-related adrenal insufficiency should be considered in boys and men with primary adrenal insufficiency with no detectable steroid-21-hydroxylase antibodies or other organ specific antibodies. […] In all at-risk patients with a relative diagnosed with ALD, ALD should be considered. […] For the diagnosis of cerebral ALD, the minimum set of MR sequences is T1 (gadolinium), T2, and FLAIR. Sedation should be used if necessary.

• #1 Adrenoleukodystrophy in the Differential Diagnosis of Boys Presenting with Primary Adrenal Insufficiency without Adrenal Antibodies – Journal of Clinical Research in Pediatric Endocrinology

  https://jcrpe.org/articles/adrenoleukodystrophy-in-the-differential-diagnosis-of-boys-presenting-with-primary-adrenal-insufficiency-without-adrenal-antibodies/doi/jcrpe.galenos.2020.2020.0214

  Given this need for early ALD diagnosis and monitoring for CALD, ALD should be included in the differential diagnosis of boys presenting with PAI without adrenal antibodies. […] Recognition of PAI without adrenal antibodies in this boy with recurrent hypoglycaemic episodes prompted repeated analysis of VLCFAs and identification of the underlying ALD diagnosis before the onset of neurological symptoms. […] PAI can result from genetic or acquired diseases that affect adrenal function. Adrenal insufficiency in ALD may arise as a result of abnormal VLCFA accumulation that alters the viscosity of adrenocortical cell membranes, and prevents the stimulatory effects of ACTH on adrenocortical cells by inhibiting ACTH receptor binding. […] ALD is estimated to account for up to 5% of unexplained PAI cases. […] These data emphasize that all boys with unexplained PAI should be screened for ALD. […] The need for early diagnosis in order to initiate current and future treatments mandates pursuit of a clear diagnosis and awareness of the need to screen boys with unexplained PAI for ALD.

• #1 X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-7-51

  The flowchart in Figure5 summarizes the recommendations for follow-up of boys and men with X-ALD. […] Follow-up in boys and men with X-ALD is important for two reasons: 1) early detection of adrenocortical insufficiency and 2) early detection of cerebral ALD to propose allogeneic hematopoietic stem cell transplantation (HCT) if a HLA-matched donor or cord blood is available. […] Despite significant mortality risk, allogeneic HCT remains the only therapeutic intervention that can arrest the progression of cerebral demyelination in X-ALD, provided the procedure is performed very early, i.e., when affected boys or men have no or minor symptoms due to cerebral demyelinating disease. […] If boys or men do not have Addisons disease it is recommended that they are evaluated yearly by an endocrinologist for adrenocortical dysfunction by measuring the plasma ACTH levels and performing an ACTH stimulation test.

• #1 X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-7-51

  Boys without neurological deficits should be monitored closely for radiological signs of cerebral ALD. […] It is important to detect cerebral ALD as early as possible, preferably in the asymptomatic stage with only moderate radiological abnormalities to discuss the possibility to perform allogeneic HCT. […] For adult men with or without signs of AMN, we advise evaluation by a neurologist yearly or bi-annually to screen for symptoms of AMN and to administer symptomatic treatment if necessary. […] For AMN there is no effective disease modifying therapy available yet. […] Regular follow-up in AMN remains important, however, mainly to provide symptomatic treatment. […] Women with X-ALD should be evaluated for the development of neurologic symptoms. […] For symptomatic women with X-ALD, we advise (as for men with AMN) a yearly evaluation by a neurologist to discuss the indication of rehabilitation, the referral to an urologist and treatment of spasticity and neuropathic pain.

• #1 Adrenoleukodystrophy – Wikipedia

  https://en.wikipedia.org/wiki/Adrenoleukodystrophy

  Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. […] The clinical presentation of ALD can vary greatly, making diagnosis difficult. […] When ALD is suspected based on clinical symptoms, the initial testing usually includes plasma very long chain fatty acid (VLCFA) determination using gas chromatography-mass spectrometry. […] Confirmation of ALD after positive plasma VLCFA determination usually involves molecular genetic analysis of ABCD1. […] Because the characteristic elevations associated with ALD are present at birth, well before any symptoms are apparent, there have been methods developed in the interests of including it in newborn screening programs. […] The Loes score is a rating of the severity of abnormalities in the brain found on MRI.

• #1 ALD: Adrenoleukodystrophy, Disease, X-Linked

  https://my.clevelandclinic.org/health/diseases/6030-adrenoleukodystrophy-ald

  ALD has no cure at this time. Treatment focuses on slowing the diseases progression and improving symptoms. […] If your child receives a diagnosis of ALD, ask your provider: Can my child receive a stem cell transplant? Does my child need steroid treatment? Whats the outlook for my child? How else can we improve my childs symptoms? Should family members get genetic testing? Are there clinical trials my child can join? […] The earlier treatment for ALD starts, the better the chances of slowing the disease. Several ALD treatments are available, including stem cell transplant, medications and supportive therapies.

• #1 Diagnosis of Adrenoleukodystrophy – DoveMed

  https://www.dovemed.com/health-topics/focused-health-topics/diagnosis-adrenoleukodystrophy/

  Adrenoleukodystrophy (ALD) is a rare, genetic disorder that affects the nervous system and adrenal glands. Early and accurate diagnosis is crucial for managing the disease and improving the quality of life for affected individuals. This article outlines the diagnostic process for ALD, highlighting key tests and considerations. […] The hallmark of ALD is elevated levels of VLCFAs in the blood. Testing for these fatty acids is a key diagnostic step. […] ABCD1 Gene Mutation Analysis: Confirmatory for ALD diagnosis. It identifies mutations in the ABCD1 gene, confirming the diagnosis and allowing for carrier testing and genetic counseling. […] The diagnosis of adrenoleukodystrophy involves a comprehensive approach, including clinical evaluation, biochemical tests, genetic testing, and imaging. Early detection and intervention are critical for managing the disease’s progression and mitigating its effects on the nervous system and adrenal function.

• #2 X-Linked Adrenoleukodystrophy | Choose the Right Test

  https://arupconsult.com/content/x-linked-adrenoleukodystrophy

  X-linked adrenoleukodystrophy (X-ALD) is a rare metabolic disorder caused by variants in the ABCD1 gene that lead to an accumulation of very long chain fatty acids (VLCFAs) in tissue. […] Early diagnosis is critical because allogeneic hematopoietic stem cell transplantation (HSCT) can slow or even halt cerebral disease progression if performed at an early stage of leukodystrophy, before neurologic symptoms manifest. […] Laboratory testing for the diagnosis of X-ALD involves measurement of VLCFAs; the detection of ABCD1 gene variants confirms the diagnosis. […] Hematopoietic stem cell transplantation (HSCT) must be performed early in the development of leukodystrophy; males with pathogenic ABCD1 gene variants therefore must undergo ongoing assessment, including evaluation of adrenocortical function and magnetic resonance imaging (MRI) of the brain, to determine if HSCT is indicated.

• #2 ALD Diagnosis | Tests, Screening and Symptoms

  https://www.navigatingald.com/what-is-ald/ald-diagnosis

  Navigating an adrenoleukodystrophy (ALD) diagnosis can come with a lot of questions. […] For those who were not diagnosed through newborn screening, an endocrinologist or geneticist/genetic counselor can confirm an ALD diagnosis by measuring very longchain fatty acids (VLCFAs) levels in blood plasma and testing for a mutation in the ABCD1 gene. […] Conversations about diagnosing ALD and genetic testing can be hard to predict because every family is unique. However, testing is critical because it can lead to diagnosis of ALD before symptoms occur. This can also help your family develop their own care plan if needed. […] In 2016, ALD was added to the USA Recommended Uniform Screening Panel (RUSP), which lists genetic diseases recommended for state newborn screening (NBS) programs. Since then, many states have begun screening for ALD. Newborn screening can be lifesaving, as early diagnosis and management of ALD is crucial.

• #2 X-Linked Adrenoleukodystrophy – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1315/

  All male infants with a positive NBS for X-ALD and a confirmed ABCD1 pathogenic variant need immediate referral to a pediatric endocrinologist for screening for primary adrenocortical insufficiency and prompt treatment to prevent life-threatening complications of primary adrenal insufficiency. […] The diagnosis of X-ALD is established in a proband by identification of abnormally elevated very long-chain fatty acids (VLCFAs) on biochemical testing and identification of a hemizygous ABCD1 pathogenic (or likely pathogenic) variant in a male or a heterozygous ABCD1 pathogenic (or likely pathogenic) variant in a female on molecular genetic testing. […] VLCFAs may be determined in serum or plasma. The characteristic elevation is in the saturated VLCFAs (especially hexacosanoic acid, abbreviated as C26:0).

• #2 Diagnosis of ALD |

  https://adrenoleukodystrophy.info/clinical-diagnosis/diagnosis-of-ald

  The diagnosis of adrenoleukodystrophy should be considered in four distinct clinical situations: […] Diagnosis is based on clinical features, most commonly progressive spastic paraparesis, and a panel of laboratory tests. […] Brain MRI is always abnormal in neurologically symptomatic men and often provides the first diagnostic clue. […] The most commonly used laboratory test worldwide for the diagnosis of ALD is the measurement of plasma very long-chain fatty acid (VLCFA) concentrations. […] Increased levels of VLCFA in plasma and/or cultured skin fibroblasts is present in approximately 85% of women with ALD; 15-20% of known women with ALD have normal plasma levels of VLCFA. […] VLCFA containing C26:0-lysoPC is elevated in all men and 99% women with ALD and is used in newborn screening for ALD.

• #2 Adrenoleukodystrophy | MedLink Neurology

  https://www.medlink.com/articles/adrenoleukodystrophy

  Genetic testing is especially important in patients with borderline very long-chain fatty acid levels or atypical features and female patients with symptoms or family history of adrenoleukodystrophy due to the less sensitive results of very long-chain fatty acid testing. […] Adrenal function should always be evaluated in the patients with X-linked adrenoleukodystrophy diagnosis. […] Once a diagnosis is made based on genetic biochemical screening, there are currently no reliable biomarkers to help with the prediction of the likely phenotype in the patient. […] Brain MRI studies are of great diagnostic value for the childhood, adolescent, and adult cerebral forms of adrenoleukodystrophy. […] The cerebral white matter involvement typically begins from the splenium of the corpus callosum and progresses to the periventricular and occipital regions. […] The posterior predominant T2 hyperintensity forms the most common MRI finding in the whole cohort and in children and adolescent age groups.

• #2 X-Linked Adrenoleukodystrophy – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1315/

  The diagnosis of X-ALD is established in a male proband with suggestive findings, elevated VLCFAs, and a hemizygous pathogenic variant in ABCD1 identified by molecular genetic testing. […] The diagnosis of X-ALD is established in a female proband with suggestive findings, elevated VLCFAs or C26:0-LPC, and a heterozygous pathogenic variant in ABCD1 identified by molecular genetic testing.

• #2 X-linked adrenoleukodystrophy: Diagnostic and follow-up system in Japan | Journal of Human Genetics

  https://www.nature.com/articles/jhg2010139

  Therefore, we established a quick diagnostic system for ALD patients using combined measurements of VLCFA in the serum and mutation analysis of the ABCD1 gene. […] Presymptomatic diagnosis by extended familial screening of probands should be valuable for early intervention and for preventing advanced cerebral symptoms. […] Carrier detection with genetic counseling, which can be done by noting increased VLCFA in plasma, and mutation analysis of the ABCD1 gene are very important to identify presymptomatic patients and other female carriers among their relatives. […] The establishment of a long-term follow-up system for these presymptomatic patients is necessary because we cannot predict suitable timing when HSCT should be done to get beneficial effects nor the subsequent clinical outcome.

• #2 Adrenoleukodystrophy – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK562328/

  Laboratory workup may show abnormal liver function and a reduced response to adrenocorticotropic hormone administration. More specific indicators of adrenoleukodystrophy include elevated concentrations of VLCFAs in plasma, skin fibroblasts, and amniocytes. […] Magnetic resonance imaging (MRI) of the brain is crucial for the evaluation of adrenoleukodystrophy. Typical MRI findings include a white matter demyelination pattern, microgyria, and germinolytic cysts in the caudothalamic groove. Further genetic testing to identify the specific mutation causing the disorder is recommended to confirm the diagnosis. […] Diagnosis of adrenoleukodystrophy requires a detailed history, physical examination, and diagnostic modalities that include VLCFA measurement, brain MRI, and specific genetic testing.

• #2 How is ALD Monitored & Managed? | It Might Be ALD

  https://www.itmightbeald.com/ald-monitoring-management

  Vigilant MRI monitoring can help identify progression to cerebral adrenoleukodystrophy (ALD). Cerebral ALD is a rapidly progressing, life-threatening disease that should be diagnosed as early as possible to help prevent irreversible brain damage. Regular MRI scans in boys diagnosed with ALD are critical to detect white matter changes indicative of progression to cerebral ALD. […] White matter changes on MRI precede the onset of symptoms, so MRI monitoring is critical as it can detect progression to cerebral ALD before any symptoms arise. […] Since there is no way to predict which patients with ALD will progress to cerebral ALD, it is important to detect cerebral ALD via MRI as early as possible, as the disease can progress very rapidly. […] Brain changes detected through MRI precede the onset of clinical symptoms of cerebral ALD by months; once these symptoms develop, it is often too late to treat effectively because of the rapid progression of the disease.

• #2 Clinical presentations |

  https://adrenoleukodystrophy.info/clinical-diagnosis/clinical-presentations

  Adrenoleukodystrophy has been diagnosed by one of the following criteria: evidence of elevated VLCFA levels or a pathogenic variant identified in the ABCD1 gene. However, there is still no evidence of adrenal or neurological involvement. […] Follow-up of pre-symptomatic boys and men with adrenoleukodystrophy is important for two reasons: 1) early detection of adrenal insufficiency, and 2) early detection of cerebral ALD by brain MRI to propose allogeneic hematopoietic stem cell transplantation (HSCT) if an HLA-matched donor or cord blood is available. […] A prospective evaluation of adrenal function in 49 neurologically pre-symptomatic boys with adrenoleukodystrophy showed that 80% already had impaired adrenal function. […] The diagnosis of adrenoleukodystrophy is rarely made during the first 3 to 5 years of clinical symptoms, unless other cases of adrenoleukodystrophy have been identified in the same family.

• #2 X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-7-51

  The flowchart in Figure5 summarizes the recommendations for follow-up of boys and men with X-ALD. […] Follow-up in boys and men with X-ALD is important for two reasons: 1) early detection of adrenocortical insufficiency and 2) early detection of cerebral ALD to propose allogeneic hematopoietic stem cell transplantation (HCT) if a HLA-matched donor or cord blood is available. […] Despite significant mortality risk, allogeneic HCT remains the only therapeutic intervention that can arrest the progression of cerebral demyelination in X-ALD, provided the procedure is performed very early, i.e., when affected boys or men have no or minor symptoms due to cerebral demyelinating disease. […] If boys or men do not have Addisons disease it is recommended that they are evaluated yearly by an endocrinologist for adrenocortical dysfunction by measuring the plasma ACTH levels and performing an ACTH stimulation test.

• #2 Adrenoleukodystrophy Clinical Practice Guidelines – 2022 Guideline Summary for Adrenoleukodystrophy

  https://www.guidelinecentral.com/guideline/2306198/

  Cerebral ALD should be considered in boys and men with white matter abnormalities on brain MRI in a pattern suggestive of ALD with or without cognitive and neurologic symptoms. […] ALD-related myelopathy should be considered in adult men and women with signs or symptoms of chronic myelopathy (gait disorder, spastic paraparesis, sphincter disturbances) with a normal MRI. […] ALD-related adrenal insufficiency should be considered in boys and men with primary adrenal insufficiency with no detectable steroid-21-hydroxylase antibodies or other organ specific antibodies. […] In all at-risk patients with a relative diagnosed with ALD, ALD should be considered. […] For the diagnosis of cerebral ALD, the minimum set of MR sequences is T1 (gadolinium), T2, and FLAIR. Sedation should be used if necessary.

• #2 Adrenoleukodystrophy in the Differential Diagnosis of Boys Presenting with Primary Adrenal Insufficiency without Adrenal Antibodies – Journal of Clinical Research in Pediatric Endocrinology

  https://jcrpe.org/articles/adrenoleukodystrophy-in-the-differential-diagnosis-of-boys-presenting-with-primary-adrenal-insufficiency-without-adrenal-antibodies/doi/jcrpe.galenos.2020.2020.0214

  Given this need for early ALD diagnosis and monitoring for CALD, ALD should be included in the differential diagnosis of boys presenting with PAI without adrenal antibodies. […] Recognition of PAI without adrenal antibodies in this boy with recurrent hypoglycaemic episodes prompted repeated analysis of VLCFAs and identification of the underlying ALD diagnosis before the onset of neurological symptoms. […] PAI can result from genetic or acquired diseases that affect adrenal function. Adrenal insufficiency in ALD may arise as a result of abnormal VLCFA accumulation that alters the viscosity of adrenocortical cell membranes, and prevents the stimulatory effects of ACTH on adrenocortical cells by inhibiting ACTH receptor binding. […] ALD is estimated to account for up to 5% of unexplained PAI cases. […] These data emphasize that all boys with unexplained PAI should be screened for ALD. […] The need for early diagnosis in order to initiate current and future treatments mandates pursuit of a clear diagnosis and awareness of the need to screen boys with unexplained PAI for ALD.

• #2 Adrenoleukodystrophy Clinical Practice Guidelines – 2022 Guideline Summary for Adrenoleukodystrophy

  https://www.guidelinecentral.com/guideline/2306198/

  All boys and men with ALD should be screened for cerebral ALD, including in the absence of neurologic or cognitive symptoms. […] A baseline MRI scan should be obtained at age 2 years. Between 2 and 12 years, male patients should be screened every 6 months. From age 12 years, screening should be yearly. […] Nonimaging biomarkers for the diagnosis of cerebral ALD are not indicated outside of a research setting. […] Transplantation eligibility should be determined by an ALD transplantation expert. […] If adrenal insufficiency is present, we recommend glucocorticoid replacement therapy by an endocrinologist.

• #2 Management and prognosis of X-linked adrenoleukodystrophy – UpToDate

  https://www.uptodate.com/contents/management-and-prognosis-of-x-linked-adrenoleukodystrophy/print

  X-linked adrenoleukodystrophy (ALD) is a peroxisomal disorder of beta-oxidation that results in accumulation of very long-chain fatty acids (VLCFAs) in all tissues. Patients with ALD are asymptomatic at birth but may develop adrenal failure, leukodystrophy, and/or myeloneuropathy (spinal cord disease and peripheral neuropathy). Disease manifestations and disease severity are highly variable among patients. […] The treatment and prognosis of ALD will be reviewed here. Other aspects of ALD are reviewed separately. (See „Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy”.) […] Patients diagnosed with ALD should be monitored for disease manifestations (leukodystrophy, myeloneuropathy, adrenal insufficiency), as detailed in the sections that follow (figure 1). […] MRI surveillance for leukodystrophy — All neurologically asymptomatic males with confirmed ALD should undergo surveillance neuroimaging with brain magnetic resonance imaging (MRI); over half of males will eventually develop a progressive leukodystrophy, the clinical effects of which may be mitigated by early treatment. (See „Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy”, section on 'Leukodystrophy’.) […] Routine surveillance in females is not recommended as leukodystrophy is rare in females.

• #2 Adrenoleukodystrophy (ALD): Causes, Types, Symptoms, Prognosis

  https://www.webmd.com/brain/what-is-adrenoleukodystrophy

  ALD genetic testing […] An inherited mutation of the ABCD1 gene causes adrenoleukodystrophy. Genetic testing can identify the four types of ALD in newborns, adults, people diagnosed with Addison’s disease, and family members who may not have symptoms of adrenoleukodystrophy. Since 2016, a newborn screening test for ALD has been available in several states. It detects high levels of very long-chain fatty acids (VLCFAs) in the blood, which confirms the presence of ALD. The screening identifies newborns at risk for cerebral ALD, which, if caught early, can be treated. You can find out whether ALD screening, also called X-linked adrenoleukodystrophy screening, is available in your state here: https://newbornscreening.hrsa.gov/your-state. […] […] How Is ALD Diagnosed? […] The illness can take time to be diagnosed since other illnesses may need to be ruled out first. Many early symptoms can be missed or blamed on more common and milder health issues such as attention deficit disorder (ADD) or learning disabilities.

• #2 Adrenoleukodystrophy | Children’s Hospital of Philadelphia

  https://www.chop.edu/conditions-diseases/pediatric-cerebral-adrenoleukodystrophy

  ALD can be diagnosed at birth through newborn screening programs or when a patient or family member begins to show symptoms. […] Early diagnosis and treatment are crucial for better chances of slowing the progression of CALD. Some states have added adrenoleukodystrophy to their newborn screening. The newborn screening is a series of special tests that check a baby for health conditions at birth. […] Early diagnosis through the newborn screening is helpful in identifying children at risk for ALD, but it can’t predict which form of the condition adrenal, cerebral or adult AMN a child will have, or when the symptoms will start to impact them, if at all. This is why it is so important for boys affected by ALD and their family members to receive care in a specialized center. […] Every child identified with ALD through the newborn screening must receive standardized neurologic monitoring throughout childhood that includes blood work and brain MRIs. This allows clinicians to see changes in the brain before the child shows any physical symptoms. This also allows treatment of adrenal insufficiency, which can be life threatening. If the care team sees anything concerning, they can provide personalized intervention immediately before a child has permanent injury to their brain. Targeted treatment of CALD has the best outcome when performed on an individual before symptoms are clinically visible.

• #2 ALD: Adrenoleukodystrophy, Disease, X-Linked

  https://my.clevelandclinic.org/health/diseases/6030-adrenoleukodystrophy-ald

  ALD has no cure at this time. Treatment focuses on slowing the diseases progression and improving symptoms. […] If your child receives a diagnosis of ALD, ask your provider: Can my child receive a stem cell transplant? Does my child need steroid treatment? Whats the outlook for my child? How else can we improve my childs symptoms? Should family members get genetic testing? Are there clinical trials my child can join? […] The earlier treatment for ALD starts, the better the chances of slowing the disease. Several ALD treatments are available, including stem cell transplant, medications and supportive therapies.

• #2 X-Linked Adrenoleukodystrophy – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1315/

  X-ALD is characterized by progressive behavioral, cognitive, and neurologic deficits; onset of symptoms ranges from childhood (typically ages 4 to 8 years) to adolescence (ages 11 to 21 years) and adulthood. […] The diagnosis is established by identification of a hemizygous ABCD1 pathogenic variant in a male or a heterozygous ABCD1 pathogenic variant in a female on molecular genetic testing. […] The three scenarios in which X-linked adrenoleukodystrophy (X-ALD) may be considered are a positive newborn screening result, a symptomatic individual, and a male who is asymptomatic but identified by family screening. […] Newborn screening (NBS) for X-ALD has been added to the recommended uniform screening panel in the United States and, to date, more than half the states have begun screening.

• #2 ALD Phenotypes: Cerebral ALD | ALD Connect

  https://aldconnect.org/what-is-ald/cerebral-ald/

  Cerebral ALD is primarily diagnosed through brain MRI. Individuals with cerebral ALD will show white matter changes, often accompanied by contrast enhancement visualized with gadolinium. A “Loes Score” is assigned to describe the severity of these white matter changes, which helps guide treatment decisions and predict prognosis. […] Early diagnosis is crucial. Brain MRI changes can appear before any symptoms develop, allowing for potentially life-saving intervention. Regular monitoring through MRI scans and neurological assessments is essential for detecting the onset of cerebral involvement in both boys and men with ALD. […] International consensus guidelines recommend that all boys and men with ALD be monitored by MRI for the development of cerebral ALD even in the absence of neurological symptoms. Monitoring is crucial to preserve the best chances for a good outcome, as treatment options are most successful when pursued at the early stages of cerebral ALD progression.

• #2 ALD: Adrenoleukodystrophy, Disease, X-Linked

  https://my.clevelandclinic.org/health/diseases/6030-adrenoleukodystrophy-ald

  Adrenoleukodystrophy (ALD) is a genetic disorder connected to the X chromosome. […] Treatment focuses on stopping or slowing the diseases progression and improving symptoms. […] ALD is a progressive disease. Treatments aim to slow the progression and improve peoples quality of life. […] Some infants are diagnosed at birth during newborn screening. Newborn screening tests babies for certain diseases. About a dozen states screen for ALD during newborn screening in the hospital. More often, parents or providers notice symptoms in a childs early years. […] Healthcare providers evaluate your childs medical and family history. If the provider suspects ALD, your child may have: Blood test to measure levels of VLCFA. Genetic test to look for gene changes linked to ALD or other conditions. Adrenocorticotropic hormone (ACTH) stimulation test to check adrenal gland function. MRI to see how ALD has affected the brain.

• #3 Adrenoleukodystrophy (ALD) | Boston Children’s Hospital

  https://www.childrenshospital.org/conditions/adrenoleukodystrophy-ald

  Genetic testing can identify the ABCD1 gene mutation that causes ALD. It also can accurately identify other members of the family who have ALD but may not be showing symptoms. […] Early diagnosis of the cerebral form of ALD is critical, because there is a narrow window during which the neurological damage can be prevented. Once the disease progresses, there is no way to replace the lost myelin or reverse the neurological damage already done. […] A newborn screening test was added to the United States Recommended Uniform Newborn Screening Panel in 2016 and is currently is available in many states. It detects elevated VLCFA levels in the blood, a clear indicator of ALD. With newborn screening, boys at risk for CALD can be identified and treated early. […] When clinicians suspect CALD, they will perform tests including a magnetic resonance imaging (MRI) scan to determine whether there is damage to the brain tissue and a blood test to measure the concentration of VLCFAs. Genetic testing may be performed at this time or later. Boys who have ALD have regularly scheduled MRIs to watch for the development of CALD.

• #3 Adrenoleukodystrophy – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK562328/

  Laboratory workup may show abnormal liver function and a reduced response to adrenocorticotropic hormone administration. More specific indicators of adrenoleukodystrophy include elevated concentrations of VLCFAs in plasma, skin fibroblasts, and amniocytes. […] Magnetic resonance imaging (MRI) of the brain is crucial for the evaluation of adrenoleukodystrophy. Typical MRI findings include a white matter demyelination pattern, microgyria, and germinolytic cysts in the caudothalamic groove. Further genetic testing to identify the specific mutation causing the disorder is recommended to confirm the diagnosis. […] Diagnosis of adrenoleukodystrophy requires a detailed history, physical examination, and diagnostic modalities that include VLCFA measurement, brain MRI, and specific genetic testing.

• #3 Adrenoleukodystrophy – United Leukodystrophy Foundation

  https://ulf.org/leukodystrophies/adrenoleukodystrophy/

  How is X-ALD diagnosed? X-ALD is diagnosed by a simple blood test that analyzes the amount of very long chain fatty acids; the levels of these molecules are elevated in X-ALD. While the test is accurate in males, in about 20% of women who are proven carriers, the test shows normal results and thus gives a “false negative” result. A DNA-based blood test is available. This test permits accurate identification of carriers by genetic testing, and if it is normal can assure a woman that she is not a carrier. Diagnostic testing, carrier screening and prenatal diagnosis are available and testing protocols are available from the United Leukodystrophy Foundation (ULF). […] If the blood test suggests X-ALD, then generally an MRI will be performed in order to assess cerebral involvement. Additionally, the patient will be evaluated for adrenal insufficiency (by another blood test), as this is a common symptom of the disease that can be corrected.

• #3 X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-7-51

  X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder. […] This review focuses on the diagnosis and management of patients with X-ALD and provides a guideline for clinicians that encounter patients with this highly complex disorder. […] If X-ALD is suspected in a male with neurological symptoms (with or without typical brain MRI abnormalities) or Addisons disease, demonstration that VLCFA are elevated in plasma confirms the diagnosis. […] For women with X-ALD, the diagnostic test of choice is mutation analysis of the ABCD1 gene, because 15% of women with X-ALD have normal plasma VLCFA levels. […] A diagnosis of X-ALD must be followed by extended family screening together with a geneticist. […] It is important to detect these complications as early as possible for treatment, as described in the section on clinical management.

• #3 Adrenoleukodystrophy Clinical Practice Guidelines – 2022 Guideline Summary for Adrenoleukodystrophy

  https://www.guidelinecentral.com/guideline/2306198/

  Cerebral ALD should be considered in boys and men with white matter abnormalities on brain MRI in a pattern suggestive of ALD with or without cognitive and neurologic symptoms. […] ALD-related myelopathy should be considered in adult men and women with signs or symptoms of chronic myelopathy (gait disorder, spastic paraparesis, sphincter disturbances) with a normal MRI. […] ALD-related adrenal insufficiency should be considered in boys and men with primary adrenal insufficiency with no detectable steroid-21-hydroxylase antibodies or other organ specific antibodies. […] In all at-risk patients with a relative diagnosed with ALD, ALD should be considered. […] For the diagnosis of cerebral ALD, the minimum set of MR sequences is T1 (gadolinium), T2, and FLAIR. Sedation should be used if necessary.

• #3 X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-7-51

  The flowchart in Figure5 summarizes the recommendations for follow-up of boys and men with X-ALD. […] Follow-up in boys and men with X-ALD is important for two reasons: 1) early detection of adrenocortical insufficiency and 2) early detection of cerebral ALD to propose allogeneic hematopoietic stem cell transplantation (HCT) if a HLA-matched donor or cord blood is available. […] Despite significant mortality risk, allogeneic HCT remains the only therapeutic intervention that can arrest the progression of cerebral demyelination in X-ALD, provided the procedure is performed very early, i.e., when affected boys or men have no or minor symptoms due to cerebral demyelinating disease. […] If boys or men do not have Addisons disease it is recommended that they are evaluated yearly by an endocrinologist for adrenocortical dysfunction by measuring the plasma ACTH levels and performing an ACTH stimulation test.

• #3 Adrenoleukodystrophy | Children’s Hospital of Philadelphia

  https://www.chop.edu/conditions-diseases/pediatric-cerebral-adrenoleukodystrophy

  ALD can be diagnosed at birth through newborn screening programs or when a patient or family member begins to show symptoms. […] Early diagnosis and treatment are crucial for better chances of slowing the progression of CALD. Some states have added adrenoleukodystrophy to their newborn screening. The newborn screening is a series of special tests that check a baby for health conditions at birth. […] Early diagnosis through the newborn screening is helpful in identifying children at risk for ALD, but it can’t predict which form of the condition adrenal, cerebral or adult AMN a child will have, or when the symptoms will start to impact them, if at all. This is why it is so important for boys affected by ALD and their family members to receive care in a specialized center. […] Every child identified with ALD through the newborn screening must receive standardized neurologic monitoring throughout childhood that includes blood work and brain MRIs. This allows clinicians to see changes in the brain before the child shows any physical symptoms. This also allows treatment of adrenal insufficiency, which can be life threatening. If the care team sees anything concerning, they can provide personalized intervention immediately before a child has permanent injury to their brain. Targeted treatment of CALD has the best outcome when performed on an individual before symptoms are clinically visible.

• #4 Adrenoleukodystrophy (ALD) | Boston Children’s Hospital

  https://www.childrenshospital.org/conditions/adrenoleukodystrophy-ald

  Genetic testing can identify the ABCD1 gene mutation that causes ALD. It also can accurately identify other members of the family who have ALD but may not be showing symptoms. […] Early diagnosis of the cerebral form of ALD is critical, because there is a narrow window during which the neurological damage can be prevented. Once the disease progresses, there is no way to replace the lost myelin or reverse the neurological damage already done. […] A newborn screening test was added to the United States Recommended Uniform Newborn Screening Panel in 2016 and is currently is available in many states. It detects elevated VLCFA levels in the blood, a clear indicator of ALD. With newborn screening, boys at risk for CALD can be identified and treated early. […] When clinicians suspect CALD, they will perform tests including a magnetic resonance imaging (MRI) scan to determine whether there is damage to the brain tissue and a blood test to measure the concentration of VLCFAs. Genetic testing may be performed at this time or later. Boys who have ALD have regularly scheduled MRIs to watch for the development of CALD.

• #4 Adrenoleukodystrophy Clinical Practice Guidelines – 2022 Guideline Summary for Adrenoleukodystrophy

  https://www.guidelinecentral.com/guideline/2306198/

  Cerebral ALD should be considered in boys and men with white matter abnormalities on brain MRI in a pattern suggestive of ALD with or without cognitive and neurologic symptoms. […] ALD-related myelopathy should be considered in adult men and women with signs or symptoms of chronic myelopathy (gait disorder, spastic paraparesis, sphincter disturbances) with a normal MRI. […] ALD-related adrenal insufficiency should be considered in boys and men with primary adrenal insufficiency with no detectable steroid-21-hydroxylase antibodies or other organ specific antibodies. […] In all at-risk patients with a relative diagnosed with ALD, ALD should be considered. […] For the diagnosis of cerebral ALD, the minimum set of MR sequences is T1 (gadolinium), T2, and FLAIR. Sedation should be used if necessary.

• #4 Orphanet: X-linked adrenoleukodystrophy

  https://www.orpha.net/en/disease/detail/43

  A rare progressive peroxisomal disorder characterized by endocrine dysfunction (adrenal failure and sometimes testicular insufficiency), progressive myelopathy, peripheral neuropathy and, variably, progressive leukodystrophy. […] If there is clinical suspicion, the diagnosis is established by determining plasma VLCFA (C26:0 and C26:0/C22:0 ratio) which is increased in all male patients; up to 15% of female patients have normal VLCFA. Recently, C26:0-lysophosphatidylcholine in bloodspots or plasma has been validated as diagnostic marker, and is elevated in all male and virtually all female patients. The diagnosis can be confirmed by ABCD1 mutation analysis. […] Testing for X-ALD is recommended in all males presenting with adrenal failure (especially in cases of isolated glucocorticoid deficiency).

• #5 What is ALD? (Adrenoleukodystrophy Explained) – ALD Alliance

  https://www.aldalliance.org/ald-support.html

  ALD is diagnosed through a blood test, which analyzes the amount of very long chain fatty acids, which are elevated in ALD. […] An MRI diagnoses cerebral ALD. Although newborn screening for ALD is available in some states it is NOT a diagnostic test. Newborn screening can, however, lead to a proper and early diagnosis upon confirmatory testing. […] If you currently live in a state which is not testing, please contact the Kennedy Krieger Laboratory, listed above, for a blood spot card.

• #6 Adrenoleukodystrophy | Baby’s First Test | Newborn Screening | Baby Health

  https://www.babysfirsttest.org/newborn-screening/conditions/adrenoleukodystrophy

  If your babys newborn screening result for ALD was out of the normal range, your babys doctor or the state screening program will contact you to arrange for your baby to have additional testing. It is important to remember that an out-of-range screening result does not necessarily mean that your child has the condition. […] Follow-up testing will involve blood testing. The blood test looks at levels of VLCFAs, which are elevated in individuals with ALD. Testing may also include testing for alterations in the ABCD1 gene. […] If the blood test shows that your baby has ALD, your doctor will discuss how to keep your baby healthy. This usually involves monitoring periodically for adrenal insufficiency with a blood test and performing a magnetic resonance imaging scan (MRI) every 6 to 12 months to detect changes due to childhood cerebral disease.

Zobacz więcej